查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1683854

西班牙醫藥物流：市場佔有率分析、產業趨勢與統計、成長預測（2025-2030 年）

Spain Pharmaceutical Logistics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

西班牙醫藥物流市場規模預計在 2025 年為 58.8 億美元，預計到 2030 年將達到 72.9 億美元，預測期內（2025-2030 年）的複合年成長率將超過 4.4%。

西班牙醫藥物流-市場-IMG1

2024年，西班牙將在「醫藥成長潛力」方面領先世界，而巴塞隆納將成為歐洲第二大生物技術投資地點。

隨著越來越多的國際生物科技新興企業和公司將重點關注巴塞隆納及其大都會區，加泰隆尼亞首都正在鞏固其作為生物科技中心的地位。報告稱，到2024年，西班牙在「醫藥成長潛力」方面將位居世界第6、歐洲第3。

西班牙蓬勃發展的製藥業將提振該國的醫藥物流市場，為溫度敏感型和一般醫藥產品的運輸和儲存帶來豐厚的機會。

西班牙有103家生產人用藥品的工廠，其中11家專門生技藥品。加上46家活性成分工廠和24家獸藥工廠，總合達173家工廠，分佈在122個業務集團。這些工廠總合僱用了 183,000 名員工（包括直接、間接和誘發就業），生產產品價值 160 億歐元（167.9 億美元）（75% 用於出口），並且在競爭力和環境永續性方面處於領先地位。

2023年，處方藥將主導西班牙醫藥市場，佔銷售額的近70%。其次是非處方藥，佔12.4%，營養產品約佔3%。當年，西班牙擁有約 22,261 家藥局，相當於每 2,130 名居民就有一家藥局。

2023年，西班牙醫藥進口額將達到約220億美元，較2022年的240億美元略為下降。值得注意的是，在分析期間內，進口額增加了4.2倍以上。

西班牙醫藥產業的強勁成長可能為全國溫度敏感型和一般醫藥產品的運輸和儲存創造重大機會，從而支持西班牙醫藥物流市場的發展。

對高效物流解決方案的需求日益成長，推動了對基礎設施、技術和服務的投資，以確保藥品安全及時地送達。因此，西班牙醫藥物流市場預計將實現顯著成長，並鞏固其作為全球醫藥供應鏈關鍵組成部分的地位。

西班牙醫藥物流市場趨勢

擴大倉儲市場

在西班牙醫藥物流市場中，倉庫在提高供應鏈效率和可靠性方面發揮著至關重要的作用。

位於戰略位置的倉庫充當配送中心，確保藥品的快速運輸。最佳放置可減少運輸時間，使製藥公司能夠為醫療保健提供者、藥房和患者提供更快的服務。這種及時性至關重要，尤其是對於緊​​急藥品和醫療緊急情況而言。

從醫院到診所，醫療保健機構都依賴倉庫來滿足其藥品需求。這些倉庫確保貨物的準確和完整，有助於維持醫療保健系統的平穩運作。

製藥業涵蓋頻譜廣泛，從常見的非處方藥到專門的昂貴藥品。倉庫熟練地管理這種多樣性，提供單獨的儲存條件，例如為疫苗和其他溫度敏感物品提供冷藏空間。

倉庫為您提供了應對市場變化所需的靈活性，包括需求波動、新產品發布和不斷變化的分銷策略。在一個快速響應市場變化至關重要的行業中，這種適應性至關重要。

新倉庫由該公司與 VGP 集團合作開發，VGP 集團是一家領先的泛歐公司，專門從事最先進的物流園區建設，預計於 2023 年第一季開始營運。

2023 年 1 月，UPS 子公司 Bomi Group 投資 1,800 萬歐元（1,934 萬美元）在馬德里開設了一個新的倉儲和配送中心。該物流中心佔地 27,578平方公尺，符合 GMP 和 GDP 標準，可容納 60,000 個托盤，是歐洲最大的醫藥倉庫之一，並創造了 150 個技術職位。

在生技藥品、專科藥物和個人化醫療進步的推動下，歐洲80%的藥品現在需要溫控運輸，馬德里設施可以滿足這項需求。

我們提供各種溫控儲存選項（-30°C、+2+8°C、+15+25°C），並配備最先進的自動揀貨系統，其錯誤率低於 0.02%。該設施按照 BREEAM 標準建造，非常注重永續運作。

西班牙醫藥物流市場倉儲和儲存能力的增加反映了對高效可靠的供應鏈解決方案日益成長的需求。隨著製藥業隨著新產品創新和市場動態而不斷發展，倉儲的角色變得越來越重要。

增強的倉儲能力將確保製藥公司能夠滿足醫療保健提供者和患者日益成長的需求，最終有助於西班牙醫療保健體系的全面改善。

學名藥市場的擴張

西班牙政府放寬了某些監管規定，促進了歐洲學名藥的快速成長。

學名藥的生產成本相對於品牌藥較低，吸引了製造商投資該行業。此外，物流公司正在推出新服務，以確保用戶獲得有關其訂單的最新資訊並提供其他附加價值服務。

西班牙是歐洲學名藥普及率最高的國家之一，得到了醫療機構和病患的大力支持。西班牙對生物相似藥的重視體現在其接受英Infliximab和Rituximab等生物製藥的生物相似藥，這些藥物對於治療類風濕性關節炎和某些癌症等疾病至關重要。

主要企業有Khan Pharma和Shinhwa Biotech。 KernPharma 的生物相似藥 Remsima（Infliximab）無縫整合到治療通訊協定中，為患者提供了更經濟的選擇。

西班牙的學名藥市場充滿活力，由 Laboratorios Normon 和 Teva Pharmaceuticals 領銜。 Laboratorios Normon 擁有多元化的產品組合，涵蓋從心血管到腫瘤學等廣泛的治療領域。同時，梯瓦製藥公司正在擴大其學名藥產品，幫助西班牙患者以可負擔的價格獲得藥品。

西班牙藥品和醫療設備管理局 (AEMPS)監督這些藥品的監管和核准，並維持嚴格的安全性和有效性基準。隨著這種情況的發展，生物相似藥和學名藥將在加強西班牙醫療保健系統和改善患者治療效果方面發揮至關重要的作用。

2024年5月，全球製藥公司Hikma Pharmaceuticals PLC（Hikma）宣布成立HIKMA ESPANA, SLU（Hikma Spain）。這項戰略舉措標誌著 Hikma 首次進軍西班牙利潤豐厚的非專利注射劑市場，該市場價值約 8.6 億美元。迄今為止，Hikma 已獲得 36 種產品的核准，並在西班牙成功上市了 25 種產品，涉及循環系統、腫瘤、中樞神經系統和抗感染疾病等各個治療領域。

學名藥在西班牙越來越受歡迎，對醫藥物流市場產生了重大影響。隨著對這些具成本效益藥品的需求不斷增加，物流供應商正在提高其有效管理分銷的能力。

其中包括採用先進的追蹤系統、最佳化供應鏈和提供全面的附加價值服務。因此，學名藥市場的成長不僅正在改變製藥業，而且還推動物流業的創新和效率，確保患者能夠及時可靠地獲得基本藥物。

西班牙醫藥物流流動產業概況

西班牙醫藥物流產業競爭激烈、充滿活力，但在國家經濟中扮演更重要的角色仍有相當大的空間。市場現有主要參與者包括 DHL Supply Chain、FedEx、Kuehne + Nagel International AG、聯合包裹服務公司和 C.H.羅賓遜。這些公司正在將自動化、人工智慧、機器學習（AI 和 ML）、區塊鏈和運輸管理系統等下一代物流解決方案技術融入其服務中，以提高供應鏈生產力、降低成本並避免錯誤。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

目錄

第 1 章 簡介

  • 調查結果
  • 調查前提
  • 研究範圍

第2章調查方法

第3章執行摘要

第4章 市場動態與洞察

  • 當前市場狀況
  • 市場促進因素
    • 藥品銷售成長推動市場
    • 人口成長推動市場
  • 市場限制
    • 確保藥品安全
    • 勞動力短缺
  • 市場機會
    • 增加冷藏倉庫
  • 產業供應鏈/價值鏈分析
  • 產業吸引力-波特五力分析
    • 供應商的議價能力
    • 消費者議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭對手之間的競爭
  • 政府的市場措施和監管
  • 市場技術趨勢
  • 深入了解西班牙第三方物流市場
  • 地緣政治與疫情將如何影響市場

第5章 市場區隔

  • 按服務
    • 運輸
      • 路
      • 鐵路
      • 航空
      • 海上運輸
    • 倉庫存放
    • 附加價值服務
  • 溫度管理
    • 溫控/低溫運輸
    • 非溫控/非低溫運輸
  • 按產品
    • 學名藥
    • 品牌藥物
  • 按應用
    • 生物製藥
    • 化學品和製藥

第6章 競爭格局

  • 市場集中度概覽
  • 公司簡介
    • DHL
    • FedEx
    • Kuehne+Nagel International AG
    • United Parcel Service
    • CH Robinson
    • CEVA Logistics
    • DB Schenker
    • Movianto
    • Agility Logistics
    • Eurotranspharma
    • CSP*
  • 其他公司

第7章 市場機會與未來趨勢

第 8 章 附錄

  • 宏觀經濟指標（GDP分佈，依活動分類）
  • 經濟統計 - 運輸及倉儲業對經濟的貢獻
簡介目錄
Product Code: 50001019

The Spain Pharmaceutical Logistics Market size is estimated at USD 5.88 billion in 2025, and is expected to reach USD 7.29 billion by 2030, at a CAGR of greater than 4.4% during the forecast period (2025-2030).

Spain Pharmaceutical Logistics - Market - IMG1

Spain is set to lead the world in 'pharma growth potential' in 2024, with Barcelona emerging as Europe's second-best hub for biotech investment.

With a growing number of international biotech startups and companies eyeing Barcelona and its metropolitan area, the Catalan capital is solidifying its position as a biotech stronghold. Reports indicate that by 2024, Spain will rank sixth globally and third in Europe for 'pharma growth potential.'

The booming pharmaceutical industry in Spain is poised to bolster the country's pharmaceutical logistics market, paving the way for lucrative opportunities in transporting and storing both temperature-sensitive and general pharmaceutical products.

Spain boasts 103 factories dedicated to producing medicines for human use, with 11 specializing in biologics. When factoring in 46 facilities for active ingredients and 24 for veterinary use, the total rises to 173 factories, spread across 122 distinct business groups. Collectively, they generate 183,000 jobs (encompassing direct, indirect, and induced employment), produce goods worth EUR 16 billion (USD 16.79 billion) (with 75% earmarked for export), and lead in both competitiveness and environmental sustainability.

In 2023, prescription medications dominated Spain's pharmaceutical market, accounting for nearly 70% of the revenue. Over-the-counter medications followed at 12.4%, while nutritional products made up about 3%. That year, Spain boasted approximately 22,261 pharmacies, translating to one pharmacy for every 2,130 residents.

In 2023, Spain's pharmaceutical imports were valued at around USD 22 billion, a slight dip from the USD 24 billion in 2022. Notably, over the analyzed period, imports surged by more than 4.2 times.

This robust growth of the pharmaceutical industry in Spain will support the advancement of the Spanish pharmaceutical logistics market by creating tremendous opportunities for the transport and storage of temperature-sensitive and general pharmaceutical products in the country.

The increasing demand for efficient logistics solutions will drive investments in infrastructure, technology, and services, ensuring the safe and timely delivery of pharmaceutical products. Consequently, the Spanish pharmaceutical logistics market is expected to experience significant growth, solidifying its position as a critical component of the global pharmaceutical supply chain.

Spain Pharmaceutical Logistics Market Trends

Expansion in Warehousing and Storage Market

In Spain's pharmaceutical logistics market, warehouses are pivotal, enhancing the supply chain's efficiency and reliability.

Strategically positioned, warehouses act as distribution hubs, ensuring the swift transportation of pharmaceuticals. Their optimal placement reduces transit times, allowing pharmaceutical companies to promptly serve healthcare providers, pharmacies, and patients. This timeliness is vital, especially for urgent medications and medical emergencies.

Healthcare entities, from hospitals to clinics, depend on warehouses for their pharmaceutical needs. These warehouses guarantee accurate and complete shipments, bolstering the healthcare system's smooth operation.

The pharmaceutical sector encompasses a broad spectrum, from common over-the-counter drugs to specialized, high-value medications. Warehouses adeptly manage this variety, offering tailored storage conditions, such as refrigerated spaces for vaccines and other temperature-sensitive items.

Warehouses offer the necessary flexibility to navigate market shifts, be it demand fluctuations, new product launches, or evolving distribution strategies. Such adaptability is vital in an industry where swift responses to market changes are paramount.

In collaboration with the VGP Group, a top pan-European firm specializing in cutting-edge logistics parks, a new warehouse is set to commence operations in the first quarter of 2023.

In January 2023, Bomi Group, a subsidiary of UPS, inaugurated its new storage and distribution hub in Madrid, backed by an EUR 18-million (USD 19.34 million)investment. Spanning 27,578m2, this GMP and GDP-compliant logistics center boasts a capacity for 60,000 pallets, positioning it among Europe's largest pharmaceutical warehouses and generating 150 skilled jobs.

With 80% of pharmaceutical products in Europe now needing temperature-controlled transport due to advancements in biologics, specialty drugs, and personalized medicine, the Madrid facility is equipped to cater to this demand.

It offers diverse temperature-controlled storage options (-30 °C, +2+8 °C, +15+25 °C) and features a cutting-edge automated order-picking system, boasting an impressive error rate of under 0.02%. Built to BREEAM standards, the facility emphasizes sustainable operations.

The increase in warehousing and storage capacity in Spain's pharmaceutical logistics market reflects the growing demand for efficient and reliable supply chain solutions. As the pharmaceutical industry continues to evolve with new product innovations and market dynamics, the role of warehouses becomes increasingly critical.

Enhanced warehousing capabilities ensure that pharmaceutical companies can meet the rising needs of healthcare providers and patients, ultimately contributing to the overall improvement of the healthcare system in Spain.

Increasing in Generic Drugs market

The Spanish government is relaxing certain regulations, contributing to the surge of generic drugs in Europe.

Low production costs of generic drugs, compared to branded counterparts, are luring manufacturers to invest in the industry. Additionally, logistics companies are rolling out new services, ensuring users stay updated on their orders, complemented by other value-added offerings.

Spain boasts one of the highest rates of generic drug penetration in Europe, underscoring robust backing from both healthcare providers and patients. A testament to Spain's dedication to biosimilars is its embrace of biosimilar versions of biologic drugs, such as infliximab and rituximab, pivotal in treating ailments like rheumatoid arthritis and specific cancers.

Leading this charge are companies like Kern Pharma and Cinfa Biotech. Kern Pharma's biosimilar, Remsima (infliximab), has seamlessly integrated into treatment protocols, offering patients a more economical choice.

Spain's generic drug landscape is vibrant, with Laboratorios Normon and Teva Pharmaceuticals at the helm. Laboratorios Normon boasts a diverse portfolio, catering to therapeutic areas from cardiovascular health to oncology. Meanwhile, Teva Pharmaceuticals is broadening its generic drug offerings, ensuring Spanish patients have access to affordable medications.

The Spanish Agency of Medicines and Medical Devices (AEMPS) oversees the regulation and approval of these drugs, upholding rigorous safety and efficacy benchmarks. As the landscape shifts, both biosimilars and generics are poised to play pivotal roles in bolstering Spain's healthcare system and enhancing patient outcomes.

In May 2024, Hikma Pharmaceuticals PLC (Hikma), a global pharmaceutical entity, proudly unveiled HIKMA ESPANA, S.L.U. (Hikma Spain). This strategic move marks Hikma's inaugural foray into Spain's lucrative generic injectable market, valued at around USD 860 million. With 36 product approvals under its belt, Hikma has successfully launched 25 products across diverse therapeutic domains in Spain, including cardiovascular, oncology, central nervous system, and anti-infectives.

The increasing penetration of generic drugs in Spain is significantly impacting the pharmaceutical logistics market. As demand for these cost-effective medications rises, logistics providers are enhancing their capabilities to manage the distribution efficiently.

This includes adopting advanced tracking systems, optimizing supply chains, and offering comprehensive value-added services. Consequently, the growth of the generic drugs market is not only transforming the pharmaceutical landscape but also driving innovation and efficiency within the logistics sector, ensuring that patients receive timely and reliable access to essential medications.

Spain Pharmaceutical Logistics Industry Overview

Spain's pharmaceutical Logistics industry is competitive and dynamic, but it still has a considerable margin to achieve a more relevant role in the national economy. A few existing major players in the market include DHL Supply Chain, FedEx, Kuehne + Nagel International AG, United Parcel Service, and CH Robinson. These companies are implementing next-generation logistics solution technologies into their services, such as automation, artificial intelligence, machine learning (AI and ML), blockchain, transportation management systems, and others, to increase supply chain productivity, reduce costs, and avoid errors.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS AND DYNAMICS

  • 4.1 Current Market Scenario
  • 4.2 Market Drivers
    • 4.2.1 Increase In Pharmaceutical Sales Is Driving The Market
    • 4.2.2 Rise In Population Is Driving The Market
  • 4.3 Marrket Restraints
    • 4.3.1 Ensure The Safety Of Medications
    • 4.3.2 Labor Shortage
  • 4.4 Market Opportunities
    • 4.4.1 Increase in Cold Storage Warehouses
  • 4.5 Industry Supply Chain/Value Chain Analysis
  • 4.6 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Consumers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry
  • 4.7 Government Initiatives and Regulations in the Market
  • 4.8 Technological Trends in the Market
  • 4.9 Insights Into The 3PL Market in Spain
  • 4.10 Impact of Geopolitics and Pandemic on the Market

5 MARKET SEGMENTATION

  • 5.1 By Services
    • 5.1.1 Transportation
      • 5.1.1.1 Road
      • 5.1.1.2 Rail
      • 5.1.1.3 Air
      • 5.1.1.4 Sea
    • 5.1.2 Storage and Warehousing
    • 5.1.3 Value Added Services
  • 5.2 By Temperature Control
    • 5.2.1 Temperature Controlled/Cold Chain
    • 5.2.2 Non-Temperature Controlled/Non-Cold Chain
  • 5.3 By Product
    • 5.3.1 Generic Drugs
    • 5.3.2 Branded Drugs
  • 5.4 By Application
    • 5.4.1 Biopharma
    • 5.4.2 Chemical Pharma

6 COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration Overview
  • 6.2 Company Profiles
    • 6.2.1 DHL
    • 6.2.2 FedEx
    • 6.2.3 Kuehne+Nagel International AG
    • 6.2.4 United Parcel Service
    • 6.2.5 C.H. Robinson
    • 6.2.6 CEVA Logistics
    • 6.2.7 DB Schenker
    • 6.2.8 Movianto
    • 6.2.9 Agility Logistics
    • 6.2.10 Eurotranspharma
    • 6.2.11 CSP*
  • 6.3 Other Companies

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

8 APPENDIX

  • 8.1 Macroeconomic Indicators (GDP Distribution, by Activity)
  • 8.2 Economic Statistics - Transport and Storage Sector Contribution to Economy